Community protocol
Third-partyRetatrutide 10mg
- 01Reconstitution solution
- 1 mL
- 02Dose
- 1 mg
- 03Syringe units
- 10 units
- 04Frequency
- 3x/week
- 05Cycle length
- 30 days
- 06Bacteriostatic water
- 1 mL
- 07Bottle size
- 10 mg
- 08Bottles needed
- 2
Retatrutide
Investigational triple agonist. Phase 2 reported the largest mean weight reduction yet published for a pharmacologic agent at 48 weeks. Phase 3 ongoing.
Overview
Retatrutide activates three hormone receptors instead of one or two. Two of them, GLP-1 and GIP, work on insulin release and appetite. The third, glucagon, does something different — it raises the body's energy expenditure and mobilizes fat from the liver. Combining appetite suppression with increased energy burn is the reason researchers expect larger effects than with earlier drugs. It is still investigational and has not completed phase 3 trials.
Retatrutide is a 39-amino-acid synthetic peptide derived from the GIP sequence, incorporating Aib substitutions for DPP-4 resistance and a C20 fatty diacid for albumin-mediated half-life extension. In vitro it shows balanced full agonism at GIPR, potent agonism at GLP-1R, and moderate agonism at the glucagon receptor (GCGR), with relative in vitro potency approximately GIPR > GLP-1R > GCGR. GCGR agonism is the pharmacologically distinguishing feature: hepatic GCGR signalling raises energy expenditure, increases fatty acid oxidation, and reduces hepatic steatosis, but also opposes the glycaemic benefit of the incretin arms. The compound's design intent is a receptor potency ratio at which the incretin-driven glycaemic control outweighs glucagon-driven hyperglycaemia while retaining the thermogenic contribution.
Research areas
MetabolicObesityMASLDDiabetes
Community-specified data
Community dosage information
Community protocol
Third-partyRetatrutide 20mg
- 01Reconstitution solution
- 2 mL
- 02Dose
- 1 mg
- 03Syringe units
- 10 units
- 04Frequency
- 3x/week
- 05Cycle length
- 30 days
- 06Bacteriostatic water
- 2 mL
- 07Bottle size
- 20 mg
- 08Bottles needed
- 1
Community protocol
Third-partyRetatrutide 30mg
- 01Reconstitution solution
- 3 mL
- 02Dose
- 1 mg
- 03Syringe units
- 10 units
- 04Frequency
- 3x/week
- 05Cycle length
- 180 days
- 06Bacteriostatic water
- 3 mL
- 07Bottle size
- 30 mg
- 08Bottles needed
- 3
Not medical guidance. These third-party figures have not been independently verified, clinically reviewed, or endorsed by DB Peptide. They may be inaccurate or unsafe and should not replace product labelling or advice from a qualified clinician.
Dosing reported in the literature
Every protocol below is reproduced from a published study or approved labelling, with its source named. These are records of what was studied — not recommendations, and not a suggestion that any of them is appropriate for any person.
| Protocol as reported | Source |
|---|---|
| Weekly subcutaneous dosing escalated over 24 weeks to maintenance arms of 1, 4, 8 or 12 mgTwo separate escalation schedules were used to reach the 8 mg and 12 mg arms; the slower schedule was associated with lower gastrointestinal adverse event rates. | Jastreboff et al., NEJM 2023 (phase 2 obesity trial protocol) |
| 0.5 mg to 12 mg weekly arms in the phase 2 type 2 diabetes trial | Rosenstock et al., The Lancet 2023 |
Trial status
Phase 2 complete in obesity, type 2 diabetes and MASLD. Phase 3 TRIUMPH programme ongoing.
Phase 1
CompletedSingle and multiple ascending dose study in healthy participants and participants with type 2 diabetes established the weekly dosing profile.
Phase 2 — obesity
Completed338 adults with obesity randomized across four dose arms. Least-squares mean weight change at 48 weeks of -24.2% at 12 mg vs -2.1% for placebo.
Phase 2 — type 2 diabetes
Completed281 adults with type 2 diabetes. HbA1c reductions up to 2.02% at 36 weeks with dose-dependent weight loss.
Phase 3 — TRIUMPH programme
ActiveMultiple registered phase 3 trials in obesity, obesity with knee osteoarthritis, and obesity with cardiovascular disease.
Reported safety signals
- Gastrointestinal adverse events were dose-dependent and the most common in phase 2, consistent with the incretin class.
- Dose-dependent increases in heart rate were observed, peaking at around 24 weeks and attenuating thereafter.
- Because glucagon receptor agonism can raise hepatic glucose output, glycaemic monitoring is a defined element of the phase 3 protocols.
- Long-term safety is unestablished — no phase 3 outcome data have been published.
Common questions
Why grade B rather than A?
Grade A requires multiple adequately powered phase 3 randomized trials with published outcomes. Retatrutide has consistent, high-quality phase 2 data across three indications, but the phase 3 TRIUMPH programme has not reported. Grade B is the ceiling until it does.
Primary sources
- 01
Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial
- 02
Retatrutide in people with obesity and type 2 diabetes: a randomised, double-blind, placebo-controlled, phase 2 trial
- 03
LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss
Medical disclaimer
This page is for informational and research purposes only. Nothing here constitutes medical advice. The compounds discussed are research chemicals. Consult a qualified clinician before starting any protocol.
How this profile was built →